Jason A Efstathiou

List of Publications by Year
in descending order

180	9,164	61857 43	45213 90
papers	citations	h-index	g-index

182	182	182	9725
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bladder cancer. Lancet, The, 2016, 388, 2796-2810.	6.3	1,031
2	Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. European Urology, 2020, 77, 38-52.	0.9	699
3	Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 329-354.	2.3	383
4	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.9	372
5	Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience. European Urology, 2012, 61, 705-711.	0.9	354
6	Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233. Journal of Clinical Oncology, 2014, 32, 3801-3809.	0.8	353
7	Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. Journal of Clinical Oncology, 2016, 34, 3648-3654.	0.8	296
8	Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. European Urology, 2014, 66, 120-137.	0.9	277
9	Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. European Urology, 2017, 71, 952-960.	0.9	253
10	Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31. Journal of Clinical Oncology, 2009, 27, 92-99.	0.8	251
11	Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06. Journal of Clinical Oncology, 2009, 27, 4055-4061.	0.8	205
12	Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02. European Urology, 2008, 54, 816-824.	0.9	179
13	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. European Urology, 2022, 81, 95-103.	0.9	158
14	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Practical Radiation Oncology, 2018, 8, 354-360.	1.1	151
15	Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nature Reviews Urology, 2015, 12, 225-235.	1.9	139
16	HIV Infection and Survival Among Women With Cervical Cancer. Journal of Clinical Oncology, 2016, 34, 3749-3757.	0.8	129
17	Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1028-1036.	0.4	122
18	Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. European Urology, 2019, 76, 59-68.	0.9	112

#	Article	IF	Citations
19	Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. European Urology, 2017, 71, 729-737.	0.9	110
20	An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discovery, 2018, 8, 288-303.	7.7	107
21	Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data Base. European Urology, 2015, 68, 768-774.	0.9	98
22	Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer. Journal of the National Cancer Institute, 2015, 107, .	3.0	97
23	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1213-1224.	2.3	93
24	Obesity and mortality in men with locally advanced prostate cancer. Cancer, 2007, 110, 2691-2699.	2.0	86
25	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. JAMA Oncology, 2021, 7, 544.	3.4	82
26	Lung Cancer Cell Line Screen Links Fanconi Anemia/BRCA Pathway Defects to Increased Relative Biological Effectiveness of Proton Radiation. International Journal of Radiation Oncology Biology Physics, 2015, 91, 1081-1089.	0.4	77
27	NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 174-185.	0.4	77
28	Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncology, The, 2018, 19, e683-e695.	5.1	74
29	Cost Implications and Complications of Overtreatment of Low-Risk Prostate Cancer in the United States. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 61-68.	2.3	72
30	Clinicalâ€“Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Results From the National Cancer Data Base. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1048-1056.	0.4	71
31	Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clinical Cancer Research, 2019, 25, 3908-3920.	3.2	71
32	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncology, The, 2022, 23, 304-316.	5.1	68
33	Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncology, 2018, 4, e175230.	3.4	65
34	Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 287-295.	0.4	62
35	EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. Cancer Research, 2014, 74, 2825-2834.	0.4	61
36	DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. Seminars in Radiation Oncology, 2015, 25, 237-250.	1.0	59

#	Article	IF	Citations
37	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncology, 2020, 6, 735.	3.4	58
38	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. Journal of Urology, 2019, 201, 528-534.	0.2	57
39	Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer. JAMA Network Open, 2020, 3, e208221.	2.8	56
40	Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. World Journal of Urology, 2016, 34, 97-103.	1.2	51
41	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	0.9	51
42	Association Between Declared Hurricane Disasters and Survival of Patients With Lung Cancer Undergoing Radiation Treatment. JAMA - Journal of the American Medical Association, 2019, 322, 269.	3.8	48
43	Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomyâ€"A Multi-Institutional Observational Study. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1046-1053.	0.4	47
44	Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 78-86.	0.4	46
45	Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 95, 454-464.	0.4	46
46	Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 78.e1-78.e12.	0.8	43
47	PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene, 2018, 37, 2793-2805.	2.6	42
48	Association of very low prostateâ€specific antigen levels with increased cancerâ€specific death in men with highâ€grade prostate cancer. Cancer, 2016, 122, 78-83.	2.0	41
49	Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. European Urology, 2016, 69, 204-210.	0.9	41
50	Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs. Frontiers in Oncology, 2015, 5, 239.	1.3	40
51	SIUâ€"ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World Journal of Urology, 2019, 37, 61-83.	1.2	40
52	Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 23-31.e3.	0.9	40
53	Establishing and Delivering Quality Radiation Therapy in Resource-Constrained Settings: The Story of Botswana. Journal of Clinical Oncology, 2016, 34, 27-35.	0.8	39
54	Developing a national radiation oncology registry: From acorns to oaks. Practical Radiation Oncology, 2012, 2, 10-17.	1.1	38

#	Article	IF	Citations
55	Long-term impact of a faculty mentoring program in academic medicine. PLoS ONE, 2018, 13, e0207634.	1.1	37
56	Adjuvant radiation therapy for early stage seminoma: Proton versus photon planning comparison and modeling of second cancer risk. Radiotherapy and Oncology, 2012, 103, 12-17.	0.3	36
57	Addressing the Growing Cancer Burden in the Wake of the AIDS Epidemic in Botswana: The BOTSOGO Collaborative Partnership. International Journal of Radiation Oncology Biology Physics, 2014, 89, 468-475.	0.4	34
58	Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers. Molecular Cancer Research, 2015, 13, 713-720.	1.5	34
59	Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. Journal of Urology, 2018, 199, 407-415.	0.2	34
60	Quality Indicators for Bladder Cancer Services: A Collaborative Review. European Urology, 2020, 78, 43-59.	0.9	34
61	Disruption of SLX4-MUS81 Function IncreasesÂthe Relative Biological Effectiveness of Proton Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 95, 78-85.	0.4	33
62	What is the best way to radiate the prostate in 2016?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 59-68.	0.8	31
63	Summary and Recommendations from the National Cancer Instituteâ€™s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.2	30
64	Practice-Based Evidence to Evidence-Based Practice: Building the National Radiation Oncology Registry. Journal of Oncology Practice, 2013, 9, e90-e95.	2.5	29
65	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. European Urology Oncology, 2020, 3, 420-423.	2.6	29
66	Outcomes in a Multi-institutional Cohort of Patients Treated With Intraoperative Radiation Therapy for Advanced or Recurrent Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 88, 618-623.	0.4	28
67	Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. European Urology, 2018, 74, 99-106.	0.9	28
68	Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting. Oncologist, 2016, 21, 731-738.	1.9	27
69	Overview of the American Society for Radiation Oncologyâ€“National Institutes of Healthâ€“American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data. International Journal of Radiation Oncology Biology Physics, 2016, 95, 873-879.	0.4	27
70	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer, 2016, 122, 1505-1512.	2.0	27
71	Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treatment Reviews, 2018, 70, 88-97.	3.4	26
72	Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies. European Urology Oncology, 2019, 2, 79-87.	2.6	26

#	Article	IF	Citations
73	Beyond a moonshot: insurance coverage for proton therapy. Lancet Oncology, The, 2016, 17, 559-561.	5.1	25
74	How Will Big Data Improve Clinical and Basic Research in Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 895-904.	0.4	25
75	Longâ€term quality of life after definitive treatment for prostate cancer: patientâ€reported outcomes in the second posttreatment decade. Cancer Medicine, 2017, 6, 1827-1836.	1.3	25
76	Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care. Prostate Cancer and Prostatic Diseases, 2019, 22, 509-521.	2.0	25
77	Life, Liberty, and the Pursuit of Protons: An Evidence-Based Review of the Role of Particle Therapy in the Treatment of Prostate Cancer. Cancer Journal (Sudbury, Mass), 2009, 15, 312-318.	1.0	24
78	The Rationale for Post-Operative Radiation in Localized Bladder Cancer. Bladder Cancer, 2017, 3, 19-30.	0.2	22
79	Multicriteria plan optimization in the hands of physicians: a pilot study in prostate cancer and brain tumors. Radiation Oncology, 2017, 12, 168.	1.2	22
80	Proton therapy for prostate cancer: A review of the rationale, evidence, and current state. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 628-636.	0.8	20
81	Body Mass Index and Prostate-Specific Antigen Failure Following Brachytherapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1302-1308.	0.4	19
82	Immunotherapy and Radiation â€“ A New Combined Treatment Approach for Bladder Cancer?. Bladder Cancer, 2015, 1, 15-27.	0.2	19
83	Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2022, 112, 294-303.	0.4	19
84	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patientâ€“data Network Meta-analysis from the MARCAP Consortium. European Urology, 2022, 82, 106-114.	0.9	19
85	Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. Practical Radiation Oncology, 2017, 7, e125-e133.	1.1	18
86	Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1188-1193.	0.4	18
87	Bladder-sparing approaches to invasive disease. World Journal of Urology, 2006, 24, 517-529.	1.2	17
88	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. Urology, 2014, 83, 1316-1321.	0.5	17
89	Cancer in Botswana: The Second Wave of AIDS in Subâ€Saharan Africa. Oncologist, 2013, 18, 777-778.	1.9	16
90	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. Journal of Urology, 2018, , .	0.2	16

#	Article	IF	Citations
91	Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 272.e1-272.e9.	0.8	16
92	The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. European Urology Focus, 2016, 2, 480-487.	1.6	15
93	Management and outcomes of clinical stage IIA/B seminoma: Results from the National Cancer Data Base 1998-2012. Practical Radiation Oncology, 2016, 6, e249-e258.	1.1	15
94	Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. Journal of Urology, 2019, 201, 721-727.	0.2	15
95	Association between very small tumour size and increased cancerâ€specific mortality after radical prostatectomy in lymph nodeâ€positive prostate cancer. BJU International, 2016, 118, 279-285.	1.3	14
96	Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. Acta OncolÃ³gica, 2017, 56, 575-581.	0.8	14
97	18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review. Prostate Cancer and Prostatic Diseases, 2021, 24, 997-1006.	2.0	14
98	Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601. Journal of Clinical Oncology, 2022, 40, 3172-3179.	0.8	14
99	National Trends in the Recommendation of Radiotherapy After Prostatectomy for Prostate Cancer Before and After the Reporting of a Survival Benefit in March 2009. Clinical Genitourinary Cancer, 2015, 13, e167-e172.	0.9	13
100	Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?. Translational Andrology and Urology, 2016, 5, 702-710.	0.6	13
101	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 213-218.	0.9	13
102	MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment. International Journal of Radiation Oncology Biology Physics, 2019, 104, 197-206.	0.4	13
103	Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancerâ€“Specific Mortality. JAMA Network Open, 2022, 5, e2211869.	2.8	13
104	The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 10.e7-10.e14.	0.8	12
105	POETIC (Program for Enhanced Training in Cancer): An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. Oncologist, 2019, 24, 1557-1561.	1.9	12
106	INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.. Journal of Clinical Oncology, 2021, 39, 428-428.	0.8	12
107	Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. European Urology Oncology, 2022, 5, 304-313.	2.6	12
108	Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy. Journal of Urology, 2021, 206, 29-36.	0.2	12

#	Article	IF	Citations
109	Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2021, 19, 362-368.	0.9	12
110	Cervical Brachytherapy Exchange: Steps Toward Oncology Capacity Building in Botswana. Oncologist, 2014, 19, e1-e2.	1.9	11
111	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 53-64.	0.8	11
112	Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 430.e1-430.e7.	0.8	11
113	Bladder Preservation Strategies. Hematology/Oncology Clinics of North America, 2015, 29, 289-300.	0.9	10
114	The impact of MRE11 in nuclear to cytoplasmic ratio on outcomes in muscle invasive bladder cancer an analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233.. Journal of Clinical Oncology, 2017, 35, 343-343.	0.8	9
115	Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.. Journal of Clinical Oncology, 2020, 38, 276-276.	0.8	9
116	The current state of randomized clinical trial evidence for prostate brachytherapy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 599-610.	0.8	8
117	Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 567-584.	0.9	8
118	Assessment of Proton Beam Therapy Use Among Patients With Newly Diagnosed Cancer in the US, 2004-2018. JAMA Network Open, 2022, 5, e229025.	2.8	8
119	Postoperative radiation for prostate cancer. Lancet, The, 2012, 380, 1974-1976.	6.3	7
120	Global Radiation Oncology From the Trainee Perspective: A View From Beyond the Bunker. International Journal of Radiation Oncology Biology Physics, 2016, 94, 438-439.	0.4	7
121	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 563-569.e3.	0.9	7
122	Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. Advances in Radiation Oncology, 2017, 2, 140-147.	0.6	7
123	Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy. Clinical Genitourinary Cancer, 2021, 19, 41-46.e1.	0.9	7
124	HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana. JCO Global Oncology, 2022, 8, e2100163.	0.8	7
125	Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. Transplantation Proceedings, 2020, 52, 2720-2725.	0.3	6
126	Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine. Frontiers in Oncology, 2021, 11, 675311.	1.3	6

#	Article	IF	Citations
127	Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nature Reviews Urology, 2021, , .	1.9	6
128	INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancerâ€"SWOG/NRG1806.. Journal of Clinical Oncology, 2020, 38, TPS586-TPS586.	0.8	6
129	Quantitative study of prostate cancer using three dimensional fiber tractography. World Journal of Radiology, 2016, 8, 397.	0.5	6
130	Development and validation of contouring guidelines for post-cystectomy adjuvant radiation of bladder cancer.. Journal of Clinical Oncology, 2016, 34, 409-409.	0.8	6
131	Association of Race With Receipt of Proton Beam Therapy for Patients With Newly Diagnosed Cancer in the US, 2004-2018. JAMA Network Open, 2022, 5, e228970.	2.8	6
132	Painting Dose: The ART of Radiation. International Journal of Radiation Oncology Biology Physics, 2016, 96, 722-728.	0.4	5
133	Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience. Clinical Genitourinary Cancer, 2018, 16, 21-27.e1.	0.9	5
134	Impact of Community-Based Clinical Breast Examinations in Botswana. JCO Global Oncology, 2021, 7, 17-26.	0.8	5
135	Feasibility of Same-Day Prostate Fiducial Markers, Perirectal Hydrogel Spacer Placement, and Computed Tomography and Magnetic Resonance Imaging Simulation for External Beam Radiation Therapy for Low-Risk and Intermediate-Risk Prostate Cancer. Practical Radiation Oncology, 2022, 12, e117-e122.	1.1	5
136	Re: Radiotherapy with or without Chemotherapy in Muscle-invasive Bladder Cancer. European Urology, 2013, 63, 181-182.	0.9	4
137	Re: MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer. European Urology, 2015, 67, 975.	0.9	4
138	Safeguarding Autonomy of Patients With Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 103, 81-83.	0.4	4
139	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	0.9	4
140	Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer, 2016, 2, 203-213.	0.2	3
141	Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. Practical Radiation Oncology, 2018, 8, 206-212.	1.1	3
142	Setting the stage for bladder preservation. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 209-212.	0.8	3
143	Protons Versus Photons for Prostate Cancer: An Answer That Is Long Overdue and Coming. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1098-1100.	0.4	3
144	Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211â€"2. European Urology, 2016, 69, 212-213.	0.9	2

#	Article	IF	Citations
145	Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Glacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952â€“60. Methodological Issues to Avoid Misinterpretation. European Urology, 2017, 72, e64-e65.	0.9	2
146	Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol 2019;76:69â€“70. European Urology, 2019, 76, 71-72.	0.9	2
147	Standard Versus Hypofractionated Radiation Therapy for Bladder Cancer: New Insights, but Questions Remain. International Journal of Radiation Oncology Biology Physics, 2021, 111, 113-116.	0.4	2
148	Early salvage versus adjuvant post-prostatectomy radiation therapy: Long-term results of a large institutional experience.. Journal of Clinical Oncology, 2016, 34, 99-99.	0.8	2
149	Response. Journal of the National Cancer Institute, 2015, 107, djv201.	3.0	1
150	Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2016, 315, 1054.	3.8	1
151	Routine bladder cancer treatment dictates divergence from trial-derived regimens: Results of treatment at 44 radiotherapy centers. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 9.e19-9.e25.	0.8	1
152	Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Surgery, 2019, 154, 184.	2.2	1
153	The Program for Enhanced Training in Cancer: An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. JCO Global Oncology, 2020, 6, 13-13.	0.8	1
154	The impact of a positive family history on clinical and pathologic outcomes of active surveillance for prostate cancer.. Journal of Clinical Oncology, 2021, 39, 225-225.	0.8	1
155	Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP).. Journal of Clinical Oncology, 2016, 34, 27-27.	0.8	1
156	Exploring multidisciplinary practice patterns in the management of muscle invasive bladder cancer (MIBC) across the U.S. and Canada in 2015.. Journal of Clinical Oncology, 2016, 34, 368-368.	0.8	1
157	Outcomes and tolerability of selective bladder preservation by combined modality therapy for invasive bladder cancer in elderly patients.. Journal of Clinical Oncology, 2017, 35, 316-316.	0.8	1
158	Treatment Trends for Prostate Cancer. JAMA - Journal of the American Medical Association, 2015, 314, 1976.	3.8	0
159	Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study. European Urology, 2016, 69, 757-758.	0.9	0
160	Introduction. Seminars in Radiation Oncology, 2017, 27, 1-2.	1.0	0
161	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomyâ€”Reply. JAMA Oncology, 2018, 4, 1620.	3.4	0
162	Editorial comment. Urology, 2019, 124, 189-190.	0.5	0

#	Article	IF	Citations
163	328. Kaposi Sarcoma in High Population ART Utilization Setting: An Observational Study in Botswana. Open Forum Infectious Diseases, 2019, 6, S174-S175.	0.4	0
164	EDITORIAL COMMENT. Urology, 2019, 133, 171-172.	0.5	0
165	EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE)â€"An ECOG-ACRIN and NRG Collaboration.. Journal of Clinical Oncology, 2021, 39, TPS4590-TPS4590.	0.8	0
166	Differences in Quality of Life Between Men and Women who Undergo Bladder Preservation with Trimodality Therapy. Bladder Cancer, 2021, 7, 279-284.	0.2	0
167	TU-G-BRB-04: Optimal Frequency of CT Imaging for Monitoring Target Volume and Estimating Delivered Dose in Standard and Hypofractionated Prostate Proton Therapy. Medical Physics, 2011, 38, 3779-3779.	1.6	0
168	Long-term outcomes after bladder-preserving combined-modality therapy for patients with muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2016, 34, 398-398.	0.8	0
169	Renal function in bladder cancer patients after trimodality therapy: Long-term results of a large institutional experience.. Journal of Clinical Oncology, 2016, 34, 453-453.	0.8	0
170	Re-irradiation of the pelvis for a genitourinary second malignant neoplasm or a local recurrence after full-dose pelvic radiotherapy for a pelvic cancer: Experience in a high-volume cancer center.. Journal of Clinical Oncology, 2016, 34, 494-494.	0.8	0
171	Risk factors for disease progression after post-prostatectomy salvage radiation: Long-term results of a large institutional experience.. Journal of Clinical Oncology, 2016, 34, 110-110.	0.8	0
172	The prognostic utility of hemoglobin and lymphocytopenia in bladder-sparing therapy.. Journal of Clinical Oncology, 2017, 35, 370-370.	0.8	0
173	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. Journal of Clinical Oncology, 2017, 35, 9-9.	0.8	0
174	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. Journal of Clinical Oncology, 2017, 2017, 9-9.	0.8	0
175	Subtyping muscle-invasive bladder cancer to assess clinical response to trimodality therapy.. Journal of Clinical Oncology, 2017, 35, 287-287.	0.8	0
176	Trends in the use of proton beam therapy among newly diagnosed cancer patients in the United States.. Journal of Clinical Oncology, 2019, 37, 6551-6551.	0.8	0
177	Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 941-948.	2.3	0
178	An analysis of trends in prostate cancer treatment from a CMS database.. Journal of Clinical Oncology, 2020, 38, e19288-e19288.	0.8	0
179	Radiotherapy use in the treatment of gastrointestinal cancers in Medicare patients: An analysis of a CMS database.. Journal of Clinical Oncology, 2020, 38, 800-800.	0.8	0
180	Accuracy of Pathologic Diagnosis in Patients With Lymphoma and Survival: A Prospective Analysis From Botswana. JCO Global Oncology, 2021, 7, 1620-1632.	0.8	0